Company Monitoring Page for Ipsen

latest headlines for company on cafepharma

Ipsen beefs up in oncology, buying US biopharma Epizyme
Pharmaforum
Mon, 06/27/22 - 10:52 am
Tags:
Ipsen, M&A, Epizye, Tazverik, cancer, oncology
First-quarter biotech risers work hard for the win
EP Vantage
Thu, 04/21/22 - 10:32 am
Tags:
biotech, AbbVie, Bayer, Ipsen, Lantheus Medical
Ipsen plans sale of consumer health business for €350m
Pharmaforum
Fri, 02/11/22 - 11:40 am
Tags:
Ipsen, M&A, consumer health, Mayoly Spindler
Ipsen withdraws NDA for rare bone disease treatment less than 3 months after winning priority review
Endpoints
Sat, 08/14/21 - 01:47 pm
Tags:
Ipsen, FDA, palovarotene
Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases
Pharmaforum
Mon, 08/2/21 - 10:54 am
Tags:
Ipsen, Exicure, neurodegenerative disease
Ipsen bets up to $363M on another shot at a debilitating condition related to Parkinson's disease
Endpoints
Thu, 07/15/21 - 11:50 pm
Tags:
Ipsen, levodopa-induced dyskinesia, IRLAB
ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen
Fierce Pharma
Thu, 05/20/21 - 12:15 pm
Tags:
ASCO 2021, Ipsen, Exelixis, Cabometyx, thyroid cancer, clinical trials
Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO
Fierce Pharma
Wed, 05/12/21 - 11:39 pm
Tags:
Exelixis, Cabometyx, Ipsen, thyroid cancer
FDA Approvals Roundup: Qwo, Tremfya, Dysport
RAPS.org
Wed, 07/15/20 - 11:19 pm
Tags:
FDA, drug approvals, Endo International, Qwo, cellulite, Ipsen, Dysport, cerebral palsy
Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 project
Fierce Pharma
Fri, 05/29/20 - 12:27 pm
Tags:
Sanofi, Paul Hudson, David Loew, Ipsen, Pharma CEOs, FerGene, vaccines
Ipsen scraps pivotal trial as partial clinical hold drags on
Fierce Biotech
Thu, 03/26/20 - 10:40 am
Tags:
Ipsen, palovarotene, clinical trials, osteochondromas
Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts
Fierce Pharma
Fri, 02/28/20 - 11:50 pm
Tags:
Spark Therapeutics, Ipsen, Rare Diseases
Ipsen takes €669M hit as palovarotene's prospects wither
Fierce Biotech
Thu, 02/13/20 - 10:47 am
Tags:
Ipsen, palovarotene
Top Companies in Pharm Country Ranked by Revenue
BioSpace
Fri, 02/7/20 - 11:46 pm
Tags:
Connecticut, New York, New Jersey, Pennsylvania, Rhode Island, Merck, Bristol-Myers Squibb, Regeneron, Ipsen, Ovid Therapeutics, Codagenix
Ipsen’s quick fix backfires
EP Vantage
Fri, 01/24/20 - 10:48 am
Tags:
Ipsen, bone disease, palovarotene
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
Bloomberg
Fri, 12/6/19 - 09:50 am
Tags:
Ipsen, Somatuline, FDA, fibrodysplasia ossificans progressiva, osteochondromas
Ipsen doubles down on rare bone disease
EP Vantage
Wed, 10/16/19 - 07:18 pm
Tags:
Ipsen, FOP, BLU-782, Blueprint Medicines, Clementia Pharmaceuticals
FDA approves Ipsen’s Dysport to treat upper limb spasticity in children
Pharmaceutical Business Review
Fri, 09/27/19 - 09:43 am
Tags:
Ipsen, Dysport, upper limb spasticity, FDA
Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Pharmaceutical Business Review
Mon, 07/8/19 - 10:25 am
Tags:
Ipsen, Servier, liposomal irinotecan, pancreatic cancer
Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Endpoints
Mon, 02/25/19 - 10:04 am
Tags:
M&A, Ipsen, Clementia Pharmaceuticals, Rare Diseases

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.